Utility of High-Sensitivity Modified Glasgow Prognostic Score in Cancer Prognosis: A Systemic Review and Meta-Analysis

Wu, Tsung-Hsien; Tsai, Yao-Te; Chen, Kuan-Yin; Yap, Wing-Keen; Luan, Chih‐Wei

doi:10.3390/ijms24021318

Cited by 12 publications

(9 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some studies have demonstrated the utility of a combination of CRP levels and other serum markers (Table II). The Glasgow prognostic score (GPS), modified GPS (mGPS), and high-sensitivity mGPS (HS-mGPS) have been shown to predict oncological outcomes in several types of cancers, including STS (50)(51)(52). A combination of CRP levels and hypoalbuminemia was applied to these scoring systems.…”

Section: Prognostic Tool Using Crp For Predicting Survival In Stsmentioning

confidence: 99%

C‑reactive protein and related predictors in soft tissue sarcoma (Review)

Nakamura,

Asanuma,

Hagi

et al. 2023

Mol Clin Oncol

View full text Add to dashboard Cite

C-reactive protein (CRP) is a useful predictor of poor survival in patients with several types of cancer because inflammation is strongly associated with cancer progression. The production of CRP in hepatocytes appears to be primarily induced at the transcriptional level following the elevation of circulating interleukin-6 (IL-6), which is produced by various cell types, including cancer cells and cancer-associated fibroblasts. Serum CRP levels are associated with serum IL-6 levels in patients with soft tissue sarcoma (STS). Additionally, patients with elevated CRP levels had worse oncological outcomes than those with normal CRP levels. It has been attempted to combine CRP levels with other inflammatory or immune markers, and the utility of this has been demonstrated. Therefore, a novel treatment strategy should be developed for patients with STS with elevated CRP levels. The present review aimed to clarify the role of CRP levels and related tools in predicting clinical outcomes in patients with STS.

show abstract

Section: Prognostic Tool Using Crp For Predicting Survival In Stsmentioning

confidence: 99%

C‑reactive protein and related predictors in soft tissue sarcoma (Review)

Nakamura,

Asanuma,

Hagi

et al. 2023

Mol Clin Oncol

View full text Add to dashboard Cite

show abstract

“…The Glasgow Prognostic Score (GPS), which includes C-reactive protein (CRP) and serum albumin, is a succinct prognostic tool that captures both the systemic inflammatory response and declining nutritional status [13]. The GPS has been extensively validated in oncology patients, and it has also been associated with chronic kidney disease (CKD) progression and mortality in prevalent Asian dialysis patients [13][14][15][16].…”

Section: Introductionmentioning

confidence: 99%

Glasgow prognostic score as an outcome predictor for patients initiating hemodialysis

Ștefan,

Zugravu,

Stancu

2023

Ther Apher Dial

View full text Add to dashboard Cite

IntroductionThis retrospective study examined the relationship between the Glasgow Prognostic Score (GPS) at hemodialysis (HD) initiation and overall/cardiovascular mortality.MethodsA total of 264 patients starting HD between 2014 and 2015 at a single center were studied. Follow‐up persisted until therapy change, death, or study end (December 31, 2021), with a median of 6.8 years.ResultsPatients with a higher GPS more frequently had emergent HD initiation and showed increased eGFR at initiation. During follow‐up, 60% of patients died, with cardiovascular disease being the leading cause. Univariate analysis revealed a significant difference in median survival time across GPS classes. Cox proportional hazard models confirmed a significant association between GPS and mortality.ConclusionsWe report a significant association between GPS at HD initiation and mortality. GPS may prove useful as a prognostic tool for identifying high‐risk patients, underscoring the need for future research to validate these findings and explore the potential of GPS‐based interventions.

show abstract

“…The modi ed Glasgow Prognostic Score (mGPS) is a validated predictive model for systemic in ammatory response (SIR), calculated based on Creactive protein (CRP) levels representing the level of in ammation and albumin levels representing the nutritional status [9]. Numerous studies have shown that increased GPS or mGPS level indicates poor prognosis in patients with mCRC, lung, oesophageal, and gastric cancers [10][11][12][13].…”

Section: Introductionmentioning

confidence: 99%

Systemic inflammation plays a central role in sarcopenia and prognosis of patients with metastatic colorectal cancer: A retrospective study

Yang,

Tang,

Qiu

et al. 2023

Preprint

View full text Add to dashboard Cite

Background Systemic inflammatory response (SIR) affects the prognosis of metastatic colorectal cancer (mCRC) and is reportedly a crucial triggering factor for sarcopenia. Furthermore, sarcopenia has recently been reported to be associated with shorter overall survival in patients with mCRC; however, the existing evidence is insufficient and inconsistent. Therefore, we aimed to investigate the impact of the body composition of patients on the prognosis of mCRC in relation to the SIR. Methods This retrospective study collected data from 317 patients with mCRC in China between January 2015 and 2020. The data of patients at baseline and after three cycles of first-line treatment were evaluated, primarily including modified Glasgow Prognostic Score (mGPS) [inflammation level calculated using C-reactive protein (CRP) and albumin], body composition parameters [total adipose tissue index, total adipose tissue density, skeletal muscle index (SMI), and skeletal muscle density (SMD)], and overall survival. The Kaplan–Meier survival curve was drawn to verify the predictive effect of mGPS on overall survival. Furthermore, non-parametric tests and the empirical cumulative distribution function were used to evaluate the relationship between mGPS and body composition and univariate and multivariate Cox regression analysis was used to determine the factors related to the prognosis of mCRC. Results In our cohort, the survival curve showed that the baseline mGPS had a strong predictive effect on overall survival. The empirical cumulative distribution function showed that a high mGPS level was associated with a low baseline SMD and SMI and a low SMI after treatment, indicating a significant correlation between sarcopenia and mGPS. Univariate analysis showed that factors affecting prognosis included CRP, albumin, mGPS, and specific body compositions. In multivariate analysis, only mGPS retained independent prognostic value, and a high baseline mGPS level indicated poor prognosis. Conclusions Regarding SIR, we found that body composition and overall survival were affected in patients with mCRC, and sarcopenia and poor prognosis had no direct causal relationship. Furthermore, mGPS was found to be a simple and effective prognostic factor; therefore, it should be monitored during treatment. These findings could help clinicians formulate effective individualised anti-inflammatory strategies and improve the prognosis of mCRC.

show abstract

Utility of High-Sensitivity Modified Glasgow Prognostic Score in Cancer Prognosis: A Systemic Review and Meta-Analysis

Cited by 12 publications

References 48 publications

C‑reactive protein and related predictors in soft tissue sarcoma (Review)

C‑reactive protein and related predictors in soft tissue sarcoma (Review)

Glasgow prognostic score as an outcome predictor for patients initiating hemodialysis

Systemic inflammation plays a central role in sarcopenia and prognosis of patients with metastatic colorectal cancer: A retrospective study

Contact Info

Product

Resources

About